Lv41
640 积分 2025-10-10 加入
Lineage-specific transcription factor landscape of thymic neuroendocrine tumors
24天前
已完结
Cabozantinib for Advanced Grade 3 Neuroendocrine Tumors: Subgroup Analysis of the Phase 3 CABINET Trial (Alliance A021602)
24天前
已完结
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study
24天前
已完结
The lesser the better? A systematic review and meta‐analysis of resection strategy in lung neuroendocrine tumors
24天前
已完结
Analysis of SCLC subtype markers ( ASCL1 , NEUROD1 , POU2F3 , YAP1 ), DLL3 , OTP, and TTF1 in 300 lung carcinoids and enteropancreatic neuroendocrine tumours
24天前
已完结
Whole-Slide Imaging and Radiological Features Predict Clinical Outcomes in Patients With Neuroendocrine Tumors of the Lung
24天前
已完结
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
24天前
已完结
European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids
24天前
已完结
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use
24天前
已完结
Safety, Efficacy, and Central Nervous System Control in Patients with High Baseline Risk Factors Treated with Tarlatamab for SCLC or Extrapulmonary Small Cell Carcinoma
24天前
已完结
皖公网安备34019202002308
